Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by lnatolion Oct 04, 2021 6:40am
163 Views
Post# 33959721

RE:RE:RE:Mugs

RE:RE:RE:MugsA wise investor once told me that it is not about how much money a company has but look to see if they are in a position to make money.  That is why I invested in GUD.  Regardless of past performance I believe this company is now in a good position to make money as do other professional analysts.  All i hear is rhetoric of past performance.  You could go thru thousands and thousands of company's that have gone through this and made good.  Your arguments for the most part is moot.  If you are not shorting or have no shares then kindly move on as you are making no new points just rehashing the same thing on and on and on.  Tiring.  I come here for info not for people dealing with spite.
<< Previous
Bullboard Posts
Next >>